

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/071,350	02/08/2002	Michael J. Corey		2604
26389	7590 02/09/2004		EXAM	INER
CHRISTENSEN, O'CONNOR, JOHNSON, KINDNESS, PLLC 1420 FIFTH AVENUE			LEARY, L	OUISE N
SUITE 2800	AVENUE		ART UNIT	PAPER NUMBER
SEATTLE, V	VA 98101-2347		1654	

DATE MAILED: 02/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/071,350	COREY ET AL.			
Office Action Summary	Examiner	Art Unit			
	Louise N. Leary	1654			
The MAILING DATE of this communication Period for Reply	n appears on the cover sheet wi	th the correspondence address			
A SHORTENED STATUTORY PERIOD FOR R THE MAILING DATE OF THIS COMMUNICATI - Extensions of time may be available under the provisions of 37 C after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, If NO period for reply is specified above, the maximum statutory provided to the provided period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ON. FR 1.136(a). In no event, however, may a ron. a reply within the statutory minimum of third beriod will apply and will expire SIX (6) MON statute, cause the application to become AE	eply be timely filed y (30) days will be considered timely. ITHS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on					
2a) This action is FINAL . 2b) ⊠	_				
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) ☐ Claim(s) 1-20 is/are pending in the application Papers 4a) Of the above claim(s) is/are with 5) ☐ Claim(s) 14-20 is/are allowed. 6) ☐ Claim(s) 1-9 is/are rejected. 7) ☐ Claim(s) 10-13 is/are objected to. 8) ☐ Claim(s) are subject to restriction and application Papers 9) ☐ The specification is objected to by the Example 10) ☐ The drawing(s) filed on 08 February 2002	hdrawn from consideration. and/or election requirement. aminer.	objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of: 1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International B * See the attached detailed Office action for	ments have been received. ments have been received in A e priority documents have beer sureau (PCT Rule 17.2(a)).	Application No I received in this National Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-943) Information Disclosure Statement(s) (PTO-1449 or PTO/5 Paper No(s)/Mail Date 9-16-2002.	18) Paper Not	Summary (PTO-413) s)/Mail Date Informal Patent Application (PTO-152) 			

1. Claims 1-20 are pending in this application.

2. Claims 1-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Regarding claim 1, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

Correction is required to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- I. Claims 1-9 are rejected under 35 U.S.C. 102(a) as being anticipated by Corey et al (J. Immuno. Methods; V. 207(1);pp. 43-51; Aug 22,1997).

Corey et al disclose a luminometric assay for measuring cell death or membrane damage in a sample. Corey et al specifically disclose "The assay measures the release of glyceraldehydes-3-phosphate dehydrogenase (G3PDH) from dead or damaged cells by coupling its enzymatic activity to production of ATP, which in turn is measured by

well-known methods involving firefly luciferase. This is accomplished by means of a reaction series in which the activity of G3PDH is coupled with that of phosphoglycerate kinase, the next enzyme in the glycolytic pathway." See the abstract. In addition, Corey et al discloses the use of Nonidet P-40 as a detergent in the assay. See the entire document.

II. Claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Corey et al (J. Immuno. Methods; V. 207(1);pp. 43-51; Aug 22,1997).

Corey et al disclose a luminometric assay for measuring cell death or membrane damage in a sample. Corey et al specifically disclose "The assay measures the release of glyceraldehydes-3-phosphate dehydrogenase (G3PDH) from dead or damaged cells by coupling its enzymatic activity to production of ATP, which in turn is measured by well-known methods involving firefly luciferase. This is accomplished by means of a reaction series in which the activity of G3PDH is coupled with that of phosphoglycerate kinase, the next enzyme in the glycolytic pathway." See the abstract. In addition, Corey et al discloses the use of Nonidet P-40 as a detergent in the assay. See the entire document.

- 4. Claim 10-13 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 5. Claims 14-20 are allowable over the prior art of record.

Application/Control Number: 10/071,350 Page 4

Art Unit: 1654

6. Anderson et al (US Patent No. 6,653,094) has been cited to further show the state of

this art.

7. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Louise N. Leary whose telephone number is (703) 308-

3533. The examiner can normally be reached on Monday to Friday from 10 to 6:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Brenda Brumback, can be reached on (571) 272-0961. The fax phone

number for the organization where this application or proceeding is assigned is 703-

872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

LOUISE N. LEARY PRIMARY EXAMINER

January 31, 2004